<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31835">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01973218</url>
  </required_header>
  <id_info>
    <org_study_id>V72_42</org_study_id>
    <secondary_id>20130090378</secondary_id>
    <nct_id>NCT01973218</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal B Recombinant Vaccine in Adolescents Aged 11-17 Years</brief_title>
  <official_title>A Phase 3, Randomized, Observer-blind, Multicenter Study to Evaluate the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine in Healthy Subjects Aged 11 to 17 Years in Korea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the immunogenicity and safety of two doses of Novartis Meningococcal B recombinant
      vaccine administered one month apart (0, 1 month schedule) in Korean adolescents aged
      between 11-17 years.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Immunogenicity: assess percentage of subjects with SBA titer higher than or equal to 1:4</measure>
    <time_frame>1 month after last vaccination (Day 61)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assess the Safety and Immunogenicity of two doses of Novartis Meningococcal B recombinant vaccine in adolescents aged between 11-17 years</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: assess percentage and numbers of subjects with local and systemic adverse events</measure>
    <time_frame>Until Day 7 post-each vaccination</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: SAEs, medically attended AEs and AEs leading to study withdrawal</measure>
    <time_frame>Until study end (Day 61)</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: SBA GMTs, GMRs and fourfold-rise</measure>
    <time_frame>Baseline (Day 1)  and 1 month after last vaccination (Day 61)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Immunogenicity of two doses of Novartis Meningococcal B recombinant vaccine in adolescents aged between 11-17 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: ELISA GMCs and GMRs</measure>
    <time_frame>Baseline (Day 1)  and 1 month after last vaccination (Day 61)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">264</enrollment>
  <condition>Meningococcal Disease</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MenB+OMV NZ</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MenACWY-CRM and placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningoccal B recombinat vaccine</intervention_name>
    <description>Intramuscular vaccination of 2 doses of 0.5 ml in the non-dominant arm</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal ACWY-CRM conjugate vaccine and placebo</intervention_name>
    <description>Intramuscular vaccination of 2 doses of  0.5 ml in the non-dominant arm</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adolescents 11-17 years of age inclusive who have given their written assent and
             whose parent or legal guardian has given written informed consent at the time of
             enrollment

          2. Available for all the visits scheduled in the study (i.e. not planning to leave the
             area before the end of the study period)

          3. In good health as determined by the outcome of medical history, physical examination
             and clinical judgment of the investigator

          4. With a negative urine pregnancy test (for female subjects only)

        Exclusion Criteria:

          1. History of any meningococcal vaccine administration

          2. Current or previous, confirmed or suspected disease caused by N. meningitidis

          3. Household contact with and/or intimate exposure to an individual with any laboratory
             confirmed N. meningitidis infection within 60 days of enrollment;

          4. Pregnancy or nursing (breastfeeding) mothers

          5. Female subjects who have not used or do not plan to use acceptable birth control
             measures, for the 2 months duration of the study.

          6. Any serious chronic or progressive disease

          7. Family members and household members of research staff

          8. Any condition which in the opinion of the investigator may interfere with the
             evaluation of the study objectives

          9. Significant acute or chronic infection within the previous 7 days or fever within 3
             days prior to enrolment

         10. Antibiotics within 6 days prior to enrollment

         11. Known or suspected impairment/alteration of the immune system, immunosuppressive
             therapy

         12. Receipt of blood, blood products and/or plasma derivatives, or a parenteral
             immunoglobulin preparation within the previous 90 days

         13. History of severe allergic reactions after previous vaccinations or hypersensitivity
             to any vaccine component

         14. Receipt of or intent to immunize with any other vaccine(s) within 30 days prior and
             throughout the study period

         15. Participation in another clinical trial within the last 90 days or planned for during
             study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>06 Kosin University Gospel Hospital 34, amnam-dong</name>
      <address>
        <city>Seo-gu</city>
        <state>Busan</state>
        <zip>602-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>05 YuKorea University Ansan Hospital 23, Jeokgeum-ro, Danwon-gu</name>
      <address>
        <city>Ansan-si</city>
        <state>Gyeonggi-do</state>
        <zip>425-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>04 Pusan National University Yangsan Hospital 20 Geumo-ro, Mulgeum-eup</name>
      <address>
        <city>Yangsan-si</city>
        <state>Gyeongnam</state>
        <zip>626-770</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>07 Seoul National University Bundang Hospital 82, Gumi-ro 173 Beon-gil</name>
      <address>
        <city>Bundang-gu</city>
        <state>Seongnam</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>01 Seoul National University Hospital 101 Daehang-ro,</name>
      <address>
        <city>Jongno-gu</city>
        <state>Seoul</state>
        <zip>110-744,</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>03 Ewha Womans University Mokdong Hospital, Department of Pediatrics, 911-1 Mokdong</name>
      <address>
        <city>Yangcheon-gu</city>
        <state>Seoul</state>
        <zip>158-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>02 Inha University Hospital 7-206, 3rd street, Shinheung-dong, Jung-gu</name>
      <address>
        <city>Incheon</city>
        <zip>400-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 8, 2014</lastchanged_date>
  <firstreceived_date>October 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meningitis, adolescents, Meningococcal B</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
